Boston Scientific (BSX) Cash & Equivalents (2009 - 2026)

Boston Scientific (BSX) has 18 years of Cash & Equivalents data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 100.41% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 100.41% YoY), and the FY2025 full-year result was $2.0 billion, up 224.26% from the prior year.
• Cash & Equivalents declined to $1.5 billion in Q1 2026, from $2.0 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.9 billion in Q2 2024 to a low of $276.0 million in Q2 2022.
• A 5-year average of $1.1 billion and a median of $865.0 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 89.68% in 2022 and jumped 583.8% in 2024, its largest moves.
• Tracing BSX's Cash & Equivalents over 5 years: stood at $928.0 million in 2022, then retreated by 6.79% to $865.0 million in 2023, then retreated by 29.94% to $606.0 million in 2024, then jumped by 224.26% to $2.0 billion in 2025, then fell by 26.06% to $1.5 billion in 2026.
• Business Quant data shows BSX's Cash & Equivalents at $1.5 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.3 billion in Q3 2025.